Leufkens HG - Search Results

1

Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.

Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Egberts TC, Blackburn S, Persson I, Leufkens HG. Giezen TJ, et al. Among authors: leufkens hg. Drug Saf. 2009;32(12):1175-87. doi: 10.2165/11318980-000000000-00000. Drug Saf. 2009. PMID: 19916584

2

Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals.

Egberts TC, Smulders M, de Koning FH, Meyboom RH, Leufkens HG. Egberts TC, et al. Among authors: leufkens hg. BMJ. 1996 Aug 31;313(7056):530-1. doi: 10.1136/bmj.313.7056.530. BMJ. 1996. PMID: 8789980 Free PMC article. No abstract available.

3

Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data.

De Bruin ML, van Puijenbroek EP, Bracke M, Hoes AW, Leufkens HG. De Bruin ML, et al. Among authors: leufkens hg. Pharmacoepidemiol Drug Saf. 2006 Feb;15(2):99-105. doi: 10.1002/pds.1194. Pharmacoepidemiol Drug Saf. 2006. PMID: 16329159

4

Risk of aplastic anemia in patients using antiepileptic drugs.

Handoko KB, Souverein PC, van Staa TP, Meyboom RH, Leufkens HG, Egberts TC, van den Bemt PM. Handoko KB, et al. Among authors: leufkens hg. Epilepsia. 2006 Jul;47(7):1232-6. doi: 10.1111/j.1528-1167.2006.00596.x. Epilepsia. 2006. PMID: 16886988 Free article.

5

What is the harm-benefit ratio of Cox-2 inhibitors?

van Staa TP, Smeeth L, Persson I, Parkinson J, Leufkens HG. van Staa TP, et al. Among authors: leufkens hg. Int J Epidemiol. 2008 Apr;37(2):405-13. doi: 10.1093/ije/dym296. Epub 2008 Feb 8. Int J Epidemiol. 2008. PMID: 18263647

6

Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?

van Staa TP, Smeeth L, Persson I, Parkinson J, Leufkens HG. van Staa TP, et al. Among authors: leufkens hg. Pharmacoepidemiol Drug Saf. 2008 May;17(5):475-84. doi: 10.1002/pds.1568. Pharmacoepidemiol Drug Saf. 2008. PMID: 18322905

7

Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs.

Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Leufkens HG, Egberts AC. Willemen MJ, et al. Among authors: leufkens hg. Obesity (Silver Spring). 2008 Oct;16(10):2331-5. doi: 10.1038/oby.2008.362. Epub 2008 Jul 24. Obesity (Silver Spring). 2008. PMID: 18719629 Free article.

8

Safety-related regulatory actions for biologicals approved in the United States and the European Union.

Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Giezen TJ, et al. Among authors: leufkens hg. JAMA. 2008 Oct 22;300(16):1887-96. doi: 10.1001/jama.300.16.1887. JAMA. 2008. PMID: 18940975

9

Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs.

Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Leufkens HG, Egberts AC, Sturkenboom MC. Willemen MJ, et al. Among authors: leufkens hg. Pharmacoepidemiol Drug Saf. 2009 Jul;18(7):631-8. doi: 10.1002/pds.1759. Pharmacoepidemiol Drug Saf. 2009. PMID: 19415767

10

Pharmacovigilance of biopharmaceuticals: challenges remain.

Giezen TJ, Mantel-Teeuwisse AK, Leufkens HG. Giezen TJ, et al. Among authors: leufkens hg. Drug Saf. 2009;32(10):811-7. doi: 10.2165/11316550-000000000-00000. Drug Saf. 2009. PMID: 19722725 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

541 results

Search Page

Filters